CLVSのチャート
CLVSの企業情報
| symbol | CLVS |
|---|---|
| 会社名 | Clovis Oncology Inc （クロビス・オンコロジ―） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 クロービス・オンコロジー(Clovis Oncology Inc.)は米国、ヨーロッパ及び他の国際市場における抗癌剤の取得・開発・商品化に従事するバイオ医薬品会社である。同社の製品候補にはロシリチニブ、ルブラカ（ルカパリブ）及びルシチニブを含む。ルカパリブは損傷デオキシリボ核酸乳癌(DNA)の修復関連ヒト遺伝子の乳がん（BRCA）突然変異患者の治療向け単剤療法として承認されたPARP1、PARP2及びPARP3の経口小分子ポリアデノシン二リン酸（ADP）・リボースポリメラーゼ（PARP）阻害剤である。ルシチニブは、血管内皮増殖因子受容体（VEGFR）1-3、血小板由来増殖因子受容体（PDGFR）αとβ及び線維芽細胞増殖因子受容体（FGFR）1-3のチロシンキナーゼ活性の経口阻害剤である。ロシリチニブは表皮成長因子受容体（EGFR）の経口突然変異選択的阻害剤である。 クロビス・オンコロジ―は米国のバイオ医薬品会社。抗がん剤の買収、開発、商業化を手掛ける。非小細胞肺がん治療用に経口の選択的・非可逆的EGFR阻害剤CO-186を、また、卵巣がんおよびすい臓がん治療用にポリ(ADP-リボ―ス)ポリメラ―ゼ阻害剤ルカパリブの臨床開発を実施している。 |
| 本社所在地 | 5500 Flatiron Parkway Suite 100 Boulder CO 80301 USA |
| 代表者氏名 | M. James E. Barrett M.ジェームスE.バレット |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 303-625-5000 |
| 設立年月日 | 39904 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2011年 |
| 従業員数 | 360人 |
| url | www.clovisoncology.com |
| nasdaq_url | https://www.nasdaq.com/symbol/clvs |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -268.68600 |
| 終値（lastsale） | 30.34 |
| 時価総額（marketcap） | 1597388590.94 |
| 時価総額 | 時価総額（百万ドル） 1531.05 |
| 売上高 | 売上高（百万ドル） 76.12600 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 1423.143 |
| 当期純利益 | 当期純利益（百万ドル） -129.23100 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Clovis Oncology Inc revenues increased 95% to $42.3M. Net loss decreased 24% to $178.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Legal settlement loss decrease of 93% to $8M (expense) Other income increase from $948K to $2.9M (income). |
CLVSのテクニカル分析
CLVSのニュース
Nasdaq delists securities of Tuscan Holdings, Clovis Oncology, Zyversa Therapeutics 2022/12/28 22:09:37 Seeking Alpha
The Nasdaq stock announced on Wednesday delisting of securities of Tuscan Holdings Corp
Why Vallon Pharmaceuticals Shares Are Trading Higher By Over 150%; Here Are 29 Stocks Moving Premarket 2022/12/14 11:30:12 Benzinga
Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON ) shares rose 150.9% to $0.6313 in pre-market trading after the company entered into a definitive merger agreement with GRI Bio. Crown ElectroKinetics Corp. (NASDAQ: CRKN ) shares rose 71.2% to $0.2243 in pre-market trading after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share. Versus Systems Inc. (NASDAQ: VS ) rose 28% to $1.00 in pre-market trading after gaining around 7% on Tuesday. Versus Systems recently announced pricing of a $2.1 million public offering. Senti Biosciences, Inc. (NASDAQ: SNTI ) rose 17.4% to $1.69 in pre-market trading after dipping more than 21% on Tuesday. Scopus BioPharma Inc. (NASDAQ: SCPS ) shares rose 15.8% to $0.2839 in pre-market trading. Clovis Oncology, Inc. (NASDAQ: CLVS ) rose 12.8% to $0.1503 in pre-market trading after dropping 34% on Tuesday. Clovis Oncology voluntarily initiated a Chapter 11 proceeding in the U.S. Bankruptcy Court and will seek to sell its assets through a court-supervised sales process.
Wall Street’s Take On Clovis Oncology Inc. (NASDAQ: CLVS) Stock. 2022/12/13 13:00:00 Stocks Register
Clovis Oncology Inc. (NASDAQ:CLVS) traded at $0.20 at close of the session on Monday, 12/12/22, made an upward move of 0.65% on its previous day’s price. Looking at the stock we see that its previous close was $0.20 and the beta (5Y monthly) reads 0.47 with the day’s price range being $0.172 – $0.275. In … Wall Street’s Take On Clovis Oncology Inc. (NASDAQ: CLVS) Stock. Read More »
Clovis Oncology files Chapter 11, agrees to sell a drug asset 2022/12/12 22:56:23 Daily Camera
Boulder-based Clovis Oncology Inc. (Nasdaq: CLVS) filed for Chapter 11 bankruptcy protection Sunday. Its filing claims liabilities far exceeding assets.
Clovis Enters Bankruptcy With Deal to Sell Cancer-Drug Candidate to Novartis 2022/12/12 19:05:00 The Wall Street Journal
Clovis Oncology, maker of ovarian cancer drug Rubraca, has filed for chapter 11 and proposed selling a separate therapy to a Novartis affiliate.
Nasdaq delists securities of Tuscan Holdings, Clovis Oncology, Zyversa Therapeutics 2022/12/28 22:09:37 Seeking Alpha
The Nasdaq stock announced on Wednesday delisting of securities of Tuscan Holdings Corp
Why Vallon Pharmaceuticals Shares Are Trading Higher By Over 150%; Here Are 29 Stocks Moving Premarket 2022/12/14 11:30:12 Benzinga
Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON ) shares rose 150.9% to $0.6313 in pre-market trading after the company entered into a definitive merger agreement with GRI Bio. Crown ElectroKinetics Corp. (NASDAQ: CRKN ) shares rose 71.2% to $0.2243 in pre-market trading after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share. Versus Systems Inc. (NASDAQ: VS ) rose 28% to $1.00 in pre-market trading after gaining around 7% on Tuesday. Versus Systems recently announced pricing of a $2.1 million public offering. Senti Biosciences, Inc. (NASDAQ: SNTI ) rose 17.4% to $1.69 in pre-market trading after dipping more than 21% on Tuesday. Scopus BioPharma Inc. (NASDAQ: SCPS ) shares rose 15.8% to $0.2839 in pre-market trading. Clovis Oncology, Inc. (NASDAQ: CLVS ) rose 12.8% to $0.1503 in pre-market trading after dropping 34% on Tuesday. Clovis Oncology voluntarily initiated a Chapter 11 proceeding in the U.S. Bankruptcy Court and will seek to sell its assets through a court-supervised sales process.
Wall Street’s Take On Clovis Oncology Inc. (NASDAQ: CLVS) Stock. 2022/12/13 13:00:00 Stocks Register
Clovis Oncology Inc. (NASDAQ:CLVS) traded at $0.20 at close of the session on Monday, 12/12/22, made an upward move of 0.65% on its previous day’s price. Looking at the stock we see that its previous close was $0.20 and the beta (5Y monthly) reads 0.47 with the day’s price range being $0.172 – $0.275. In … Wall Street’s Take On Clovis Oncology Inc. (NASDAQ: CLVS) Stock. Read More »
Clovis Oncology files Chapter 11, agrees to sell a drug asset 2022/12/12 22:56:23 Daily Camera
Boulder-based Clovis Oncology Inc. (Nasdaq: CLVS) filed for Chapter 11 bankruptcy protection Sunday. Its filing claims liabilities far exceeding assets.
Clovis Enters Bankruptcy With Deal to Sell Cancer-Drug Candidate to Novartis 2022/12/12 19:05:00 The Wall Street Journal
Clovis Oncology, maker of ovarian cancer drug Rubraca, has filed for chapter 11 and proposed selling a separate therapy to a Novartis affiliate.
Nasdaq delists securities of Tuscan Holdings, Clovis Oncology, Zyversa Therapeutics 2022/12/28 22:09:37 Seeking Alpha
The Nasdaq stock announced on Wednesday delisting of securities of Tuscan Holdings Corp
Why Vallon Pharmaceuticals Shares Are Trading Higher By Over 150%; Here Are 29 Stocks Moving Premarket 2022/12/14 11:30:12 Benzinga
Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON ) shares rose 150.9% to $0.6313 in pre-market trading after the company entered into a definitive merger agreement with GRI Bio. Crown ElectroKinetics Corp. (NASDAQ: CRKN ) shares rose 71.2% to $0.2243 in pre-market trading after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share. Versus Systems Inc. (NASDAQ: VS ) rose 28% to $1.00 in pre-market trading after gaining around 7% on Tuesday. Versus Systems recently announced pricing of a $2.1 million public offering. Senti Biosciences, Inc. (NASDAQ: SNTI ) rose 17.4% to $1.69 in pre-market trading after dipping more than 21% on Tuesday. Scopus BioPharma Inc. (NASDAQ: SCPS ) shares rose 15.8% to $0.2839 in pre-market trading. Clovis Oncology, Inc. (NASDAQ: CLVS ) rose 12.8% to $0.1503 in pre-market trading after dropping 34% on Tuesday. Clovis Oncology voluntarily initiated a Chapter 11 proceeding in the U.S. Bankruptcy Court and will seek to sell its assets through a court-supervised sales process.
Wall Street’s Take On Clovis Oncology Inc. (NASDAQ: CLVS) Stock. 2022/12/13 13:00:00 Stocks Register
Clovis Oncology Inc. (NASDAQ:CLVS) traded at $0.20 at close of the session on Monday, 12/12/22, made an upward move of 0.65% on its previous day’s price. Looking at the stock we see that its previous close was $0.20 and the beta (5Y monthly) reads 0.47 with the day’s price range being $0.172 – $0.275. In … Wall Street’s Take On Clovis Oncology Inc. (NASDAQ: CLVS) Stock. Read More »